Phase 1CompletedINTERVENTIONAL
Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
ClinicalTrials.gov · NCT02685852 · Registry updated: 2021-05-06
- Condition / research focus
- Hyperinsulinemic Hypoglycemia
- Sponsor
- University of Minnesota
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2016-02. Completion: 2019-07-22 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Exenatide (drug) — also listed as: Byetta
- Acarbose (drug)
- Exenatide Placebo (drug)
- Acarbose Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University of Minnesota Medical CenterMinneapolis, Minnesota, United States